Poland· PL-100458876

Maviret

A glecaprevir and pibrentasvir product containing glecaprevirum + pibrentasvirum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 15 of our 19 countries.

ATC J05AP57

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedMaviretATCJ05AP57REGISTER NO.PL-100458876PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Glecaprevir and pibrentasvir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AP57 (glecaprevir and pibrentasvir), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Glecaprevir and pibrentasvir · ATC J05AP57

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Glecaprevirum + Pibrentasvirum
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Poland (PL)
ATC code
J05AP57
ATC class
Glecaprevir and pibrentasvir
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    03400930236086
  • gtin
    08054083022864

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Glecaprevir and pibrentasvir in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glecaprevir and pibrentasvir products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Glecaprevir/Pibrentasvir Abbvie
  • Iceland · Maviret
  • Liechtenstein · Maviret
  • Norway · Maviret

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/126b3f64-372e-4704-ad23-8d48abc21d5b
GET /v1/drugs/126b3f64-372e-4704-ad23-8d48abc21d5b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Granulat powlekany",
  "source": "urpl",
  "strength": "50 mg + 20 mg",
  "packaging": "Rpz ¦ EU/1/17/1213/003 ¦ 142128\n28 sasz. \n¦ UR/Z/4c/067/22 - 03400930236086 ¦ UR/Z/4c/016/23 - 03400930236086 ¦ UR/Z/4c/172/22 - 08054083022864 ¦ UR/Z/4c/091/23 - 03400930236086 ¦ UR/Z/4c/004/21 - 03400930236086 ¦ UR/Z/4c/283/25 - 03400930236086",
  "substance": "Glecaprevirum 50 mg + Pibrentasvirum 20 mg",
  "common_name": "Glecaprevirum + Pibrentasvirum",
  "pl_product_id": "100458876",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about glecaprevir and pibrentasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.